Public-registry site landscape for NCT07719023, a Idiopathic Pulmonary Fibrosis (IPF) study sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07719023 (registry record) |
| Sponsor | Shanghai Ark Biopharmaceutical Co., Ltd. |
| Condition(s) | Idiopathic Pulmonary Fibrosis (IPF) |
| Phase | PHASE3 |
| Listed sites | 1 |
| Site countries | China |
At China-Japan Friendship Hospital — one of the facilities listed on this trial — 2 other studies are actively recruiting Idiopathic Pulmonary Fibrosis (IPF) patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07719023 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →